title: A case of sterile endophthalmitis after repeated intravitreal bevacizumab injection.
abstract: OBJECTIVE
  The aim of this study was to describe a case of sterile endophthalmitis after repeated intravitreal bevacizumab injections for the treatment of choroidal neovascularization secondary to angioid streaks.
  
  
  METHODS
  This study was done as a case report.
  
  
  RESULTS
  A 57-year-old man who received a third injection of intravitreal bevacizumab for the treatment of choroidal neovascularization owing to angioid streaks developed sterile endophthalmitis. The patient's condition improved after hourly topical steroid and antibiotic drops without a sequele.
  
  
  CONCLUSIONS
  The intravitreal injection of bevacizumab has the potential for the development of sterile endophthalmitis. The patients should be warned against this possible adverse reaction, especially after repeated injections.
authors.affiliation: Ophthalmology Department, Yeditepe University Eye Hospital, Istanbul, Turkey. meldayen@hotmail.com
authors.forename: N Melda
authors.initials: NM
authors.lastname: Yenerel
authors.forename: Umut A
authors.initials: UA
authors.lastname: Dinc
authors.forename: Ebru
authors.initials: E
authors.lastname: Gorgun
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000793:Angioid Streaks / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D002939:Ciprofloxacin / Q000627:therapeutic use; D009877:Endophthalmitis / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D014822:Vitreous Body / Q000502:physiology*
chemical_list: D020533:Angiogenesis Inhibitors; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002939:Ciprofloxacin